The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations
Open accessAbstract
In Brief Purpose: A review of treat-and-extend regimens (TERs) with intravitreal anti–vascular endothelial growth factor agents in retinal diseases. Methods: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti–vascular endothelial growth factor agents, considering factors such as criteria for extension. Results: A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography–guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti–vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. Conclusion: It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases. There is a lack of consensus on the definition and optimal application of treat-and-extend regimens (TERs) in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti–vascular endothelial growth factor agents, considering factors such as criteria for extension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationFung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Self-citationIntravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 1×
“Intravitreal aflibercept (any regimen) and monthly intravitreal ranibizumab were equally effective in improving bestcorrected visual acuity over a 96-week follow-up, but the intravitreal aflibercept 2q8 group was associated with an average of 5 fewer injections.(32) In addition to it being given at a higher dose, it i…”
BackgroundSelf-citationIntravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Self-citationRanibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Self-citationHolz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615
Self-citationDiabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
Berg, K., Pedersen, T. R., Sandvik, L., & Bragadóttir, R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.041 · Cited by 392
Cited by
Artificial intelligence in retina
Schmidt-Erfurth, U., Sadeghipour, A., Gerendas, B. S., Waldstein, S. M., & Bogunović, H. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.07.004 · Cited by 779
Munk, M. R., Ceklic, L., Ebneter, A., Huf, W., Wolf, S., & Zinkernagel, M. S. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13157 · Cited by 107
Self-citationMitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators (2021) · Retina · doi:10.1097/iae.0000000000003128 · Cited by 101
Self-citationKorobelnik, J.-F., Delcourt, C., Creuzot-Garcher, C., Melaine, A., Chassetuillier, J., Lejeune, A., Bénard, S., & Dupont-Benjamin, L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1971416 · Cited by 9
Self-citation
Metadata
- Authors
- Freund, K. B., Korobelnik, J.-F., Devenyi, R., Framme, C., Galic, J., Herbert, E., Hoerauf, H., Lanzetta, P., Michels, S., Mitchell, P., Monés, J., Regillo, C., Tadayoni, R., Talks, J., & Wolf, S.
- Venue
- Retina
- Published
- 2015-08
- Volume
- 35
- Issue
- 8
- Pages
- 1489-1506
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2316418129
- Cited by
- 283
- References
- 47
- FWCI
- 25.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. https://app.cochat.ai/papers/10.1097/iae.0000000000000627
- The paper
- Freund, K. B., Korobelnik, J.-F., Devenyi, R., Framme, C., Galic, J., Herbert, E., Hoerauf, H., Lanzetta, P., Michels, S., Mitchell, P., Monés, J., Regillo, C., Tadayoni, R., Talks, J., & Wolf, S. (2015). TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina. https://doi.org/10.1097/iae.0000000000000627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.